LNAI Key Statistics, Chart & Performance
The current stock price of LNAI is 0.986 USD. In the past month the price decreased by -8.7%.
LNAI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.33 | 406.30B | ||
| AMGN | AMGEN INC | 15.27 | 179.83B | ||
| GILD | GILEAD SCIENCES INC | 15.34 | 155.92B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.67 | 117.47B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.41 | 82.37B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.67 | 52.94B | ||
| INSM | INSMED INC | N/A | 37.84B | ||
| NTRA | NATERA INC | N/A | 32.51B | ||
| BIIB | BIOGEN INC | 10.53 | 25.87B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.5 | 22.16B | ||
| INCY | INCYTE CORP | 15.64 | 19.72B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About LNAI
Company Profile
Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 29 full-time employees. The company went IPO on 2014-11-18. The firm is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
Company Info
LUNAI BIOWORKS INC
2080 Century Park East, Suite 906
Los Angeles CALIFORNIA US
Employees: 29
Phone: 14539179840
LUNAI BIOWORKS INC / LNAI FAQ
What does LNAI do?
Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 29 full-time employees. The company went IPO on 2014-11-18. The firm is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.
Can you provide the latest stock price for LUNAI BIOWORKS INC?
The current stock price of LNAI is 0.986 USD. The price decreased by -0.62% in the last trading session.
What is the dividend status of LUNAI BIOWORKS INC?
LNAI does not pay a dividend.
How is the ChartMill rating for LUNAI BIOWORKS INC?
LNAI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the market cap for LUNAI BIOWORKS INC?
LUNAI BIOWORKS INC (LNAI) has a market capitalization of 23.10M USD. This makes LNAI a Nano Cap stock.
What is the next earnings date for LNAI stock?
LUNAI BIOWORKS INC (LNAI) will report earnings on 2026-02-17.
LNAI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to LNAI.
LNAI Financial Highlights
Over the last trailing twelve months LNAI reported a non-GAAP Earnings per Share(EPS) of -7.51. The EPS decreased by -72.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1881.62% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |